India Glycols (500201) Q4 24/25 earnings summary

Executive summary

• FY25 net revenue rose 14.4% to INR 3,768 crore; consolidated revenue from operations reached INR 9,038.95 crore, EBITDA was INR 525.49 crore and PAT was INR 230.92 crore.

• Bio-Fuel and Potable Spirits led growth, while quarterly net revenue declined YoY; full-year margins and earnings improved.

Financial highlights

• Q4 consolidated revenue from operations was INR 2,188.65 crore versus INR 2,039.08 crore; EBITDA was INR 147.53 crore versus INR 109.23 crore, and PAT was INR 64.02 crore versus INR 42.21 crore.

• Q4 net revenue fell 6.8% YoY to INR 863 crore; EBITDA margin rose 532 bps to 17.1%, and PAT margin was 7.4% versus 4.5%.

• FY25 consolidated EBITDA increased to INR 525.49 crore from INR 428.09 crore; PAT rose to INR 230.92 crore from INR 172.99 crore, and EPS was INR 74.58 versus INR 55.87.

• FY25 gross revenue was INR 9,038.95 crore; net sales were INR 3,767 crore, up 14% YoY.

Segment performance

• Bio-Fuel FY25 revenue rose 103.7% to INR 1,043.55 crore and EBIT increased 83.7% to INR 56.68 crore; margin was 5.4%.

• Potable Spirits FY25 net revenue rose 22.8% to INR 1,163 crore; EBIT increased 56.1% to INR 256 crore and margin expanded 471 bps to 22%.

• BSPC FY25 revenue was INR 1,342.13 crore and EBIT INR 125.26 crore; EBIT margin improved 91 bps to 9.3%, though revenue and EBIT declined YoY.

• Ennature Biopharma FY25 revenue grew 6.9% to INR 219.37 crore, while EBIT fell 46.2% to INR 20.76 crore and margin contracted to 9.5%.

• JV revenue grew 13%, EBITDA rose 70%, and FY25 profit share was INR 46.40 crore versus INR 16.66 crore; improved cost control and product mix supported recovery.